Tim Smith

This research shows that a basophil activation test can support decision-making by clinicians when re-introduction of baked eggs in patients with allergies is a treatment being considered.

The new data addressed the lack of studies examining melanoma incidence despite the existence of research examining increases in relative numbers of advanced melanomas during the pandemic.

This research was the result of the first study assessing adaptive smoking cessation treatment within a clinical population using very few criteria for exclusion.

In this segment of her Q&A interview, Dr. Cotton discussed several major topics covered in her upcoming SHSA Conference presentation on pediatric HS.

This new Q&A interview with Dr. Cotton featured a discussion on the issues facing pediatric HS patients and other topics covered in her upcoming SHSA Conference presentation.

This new data had both a consistent long-term safety and tolerability profile with the previous short-term results for the skin disease, and there were no new safety signals recorded.

This test provides a useful approach as it can be less intensive for time and resources, less costly, and it can be conducted outside of the specialist allergy setting.

Given that this new research was an exploratory study with a smaller sample size, the study’s results may not be generalized and future studies should use more patients and institutions.

These new findings may help shape both the design and the use of an educational intervention on technology-based inhaler techniques for patients with pediatric asthma.

This new data indicates the necessity of health providers around the world to address the mental health needs of vitiligo patients, especially among those most heavily affected.

This new research demonstrated that when TNF-inhibition is effective, a shift to brodalumab treatment may be useful in suppression of psoriasis and improvement of patients’ quality of life.

This new research was prospectively gathered in Denmark and involved nationwide, population-based data as well as a uniform approach to melanoma treatment and surveillance.

This recall is defined by the FDA as Class I, known to be the most severe type given the use of such recalled products could result in harm to users.

This portion of Mosher’s interview featured a discussion about the future of respiratory care following the updates on the guidelines for pulmonary rehabilitation delivery.

During this segment of his interview, Mosher discussed center-based pulmonary rehabilitation versus telerehabilitation and other elements from the updated guidelines.

In this discussion, Dr. Mosher shared several key insights on the recently updated clinical practice guidelines for pulmonary rehabilitation delivery.

This new analysis indicated that on-treatment remission of asthma could be viewed as a realistic goal for individuals with severe asthma who are treated with biologics.

This new data suggests substantial effects of socio-economic factors in the early stages of a child’s life and their impact on health equity for pediatric asthma.

These approvals of generics by the FDA can help to provide for patients with ADHD or BED the same clinical benefits as well as risks as the drugs’ brand-name counterparts.

This systematic review highlighted the rise in studies on artificial intelligence and teledermatology for skin cancer, as well as other gaps in related research.

This new research highlights the advantages of patients with chronic spontaneous urticaria adhering to a daily maintenance non-sedating antihistamine schedule.

This analysis on a larger study population led to results which add useful data to the growing literature on sesame thresholds and may even help to assess sesame safe doses used in risk management.

This new data supports the use and feasibility of clinicians using longitudinal tobacco cessation care in the lung cancer screening setting.

The multi-center study led to several important findings, one of which being that history of biologic-use could be a factor of importance in secukinumab retention prediction.

This new data indicates that this not widely-practiced surgery for MCC, while effective, may first require initial implementation at higher-volume, regional centers for MCC due to existing infrastructure.

These new results for tralokinumab could provide safer treatment options for older atopic dermatitis patients versus conventional therapies with greater risk of adverse events and drug-drug interactions.

This new data is consistent with previous results on efficacy and on safety shown in global phase 3 studies that had enrolled both adults and adolescents.

This new analysis identified several major psoriasis risk factors, highlighting the idea that early management of such factors might help to decrease both the risk and severity of the skin disease.

This new analysis demonstrated the importance of carefully considering the unintended results of removing race correction from PFTs to prevent exacerbating disparities among Black patients.

In this latest research, the investigators noted that upadacitinib therapy may also be utilized as a treatment option for atopic dermatitis patients who experience a flare.